Working Paper Article Version 1 This version is not peer-reviewed

Serologic Response to mRNA COVID-19 Vaccination in Lymphoma Patients

Version 1 : Received: 26 July 2021 / Approved: 28 July 2021 / Online: 28 July 2021 (17:21:17 CEST)

How to cite: Jurgens, E.M.; Ketas, T.J.; Zhao, Z.; Satlin, M.J.; Small, C.B.; Sukhu, A.; Francomano, E.; Klasse, P.; Garcia, A.; Nguyenduy, E.; Bhavsar, E.; Formenti, S.; Furman, R.; Moore, J.P.; Leonard, J.P.; Martin, P. Serologic Response to mRNA COVID-19 Vaccination in Lymphoma Patients. Preprints 2021, 2021070639 Jurgens, E.M.; Ketas, T.J.; Zhao, Z.; Satlin, M.J.; Small, C.B.; Sukhu, A.; Francomano, E.; Klasse, P.; Garcia, A.; Nguyenduy, E.; Bhavsar, E.; Formenti, S.; Furman, R.; Moore, J.P.; Leonard, J.P.; Martin, P. Serologic Response to mRNA COVID-19 Vaccination in Lymphoma Patients. Preprints 2021, 2021070639

Abstract

Currently available COVID-19 mRNA vaccines have demonstrated high efficacy in clinical trials.1-3 However, cancer patients, including those with hematological malignancies, were largely excluded from these trials. In this prospective, observational study we measured anti-S protein IgG titers as well as avidity in lymphoma patients (n=67) vaccinated with a COVID-19 mRNA vaccine. Serological response rates in lymphoma patients who were treatment naïve (100% in CLL, 88.9% in other, non-CLL non-Hodgkin lymphoma patients), or who were last treated more than 24 months prior to vaccination (100% in CLL, 90% in other-NHL), were similar to healthy controls (100%). Patients on active therapy, however, had a diminished response rate (40% in CLL, 21.0% in other-NHL). No patient who received anti-CD20 monoclonal antibodies (mAb) within six months of vaccination responded. Thus, the utility of testing anti-S titers should be explored in patients on active therapy or with recent anti-CD20 mAb exposure, to assess their response to vaccination. We also propose studying passive protection with S-protein mAbs as an alternative prophylactic strategy for patients who respond poorly to vaccination.

Keywords

COVID-19; lymphoma; BNT162b2; mRNA-1273

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.